|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
|
Jun 2019
|
The Lancet Haematology
|
myelodysplastic syndromes (MDS)
|
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
|
Jan 2020
|
The New England Journal of Medicine
|
myelodysplastic syndromes (MDS)
|
|
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|
Mar 2021
|
The New England Journal of Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
|
Apr 2023
|
The Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
|
Apr 2023
|
The Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide
|
Mar 2017
|
Ther Adv Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Azacitidine in the management of patients with myelodysplastic syndromes.
|
Dec 2012
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
|
Jan 2017
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
|
Aug 2016
|
Ther Clin Risk Manag
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
|
Sep 2019
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
